CompletedPhase 4ACTRN12609000014257

Cardiovascular function with switching from Kivexa to Truvada (or from Abacavir to Tenofovir).

Cardiovascular function with switching from Kivexa to Truvada (or from Abacavir to Tenofovir) in people with Human Immunodeficiency Virus (HIV).

Sponsor

St Vincents Hospital

Enrollment

20 participants

Start Date

Sep 23, 2008

Study Type

Interventional

Conditions

Human Immunodeficiency Virus (HIV)Cardiovascular function

Summary

The purpose is to perform tonometry in HIV-infected adults before and after switching their HIV treatment from Kivexa to Truvada (or from Abacavir to Tenofovir). Hypothesis: that markers of cardiovascular function (as measured by applanation tonometry) will improve in patients switching from ABC-3TC to TDF-FTC.

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 200 Yearss

Plain Language Summary

Simplified for easier understanding

This study is for HIV-positive adults aged 18 and older who are on stable antiretroviral therapy that includes abacavir and have an undetectable viral load. It tests whether switching from abacavir to tenofovir improves heart and blood vessel health. Participants must also have a cardiovascular risk factor such as diabetes or a high Framingham score.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

using applanation tonometry to evaluate cardiovascular function in adults with HIV infection switching from ABC-3TC (Kivexa) to TDF-FTC (Truvada) or from ABC (abacavir) to TDF (tenofovir). Kivexa is

using applanation tonometry to evaluate cardiovascular function in adults with HIV infection switching from ABC-3TC (Kivexa) to TDF-FTC (Truvada) or from ABC (abacavir) to TDF (tenofovir). Kivexa is a combination HIV pill of Abacavir and lamivudine and Abacavir alone is one of the two drugs in Kivexa. Truvada, another combination pill that contains the drugs tenofovir and emtricitabine and Tenofovir alone is one of the two drugs in Truvada. Truvada and Tenofovir are the two drugs to be used in this study. This is a 24 week study Truvada dose is 1 x 300mg/200mg tablet, once daily, oral for 24 weeks. Tenofovir dose is 1 x 300mg tablet, once daily oral for 24 weeks.